ISIN | LU2208649280 |
---|---|
Valor Number | 56107579 |
Bloomberg Global ID | UBSEBQL LX |
Fund Name | UBS (Lux) Equity Fund - Biotech (USD) QL-acc |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
8098 Zürich, Schweiz E-Mail: ubs-am-wholesale-switzerland@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS Global Asset Management Basel Phone: +41 61 288 20 20 |
Asset Class | Equities |
EFC Category | Equity Global Advanced Markets |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations. |
Peculiarities |
Current Price * | 98.26 USD | 21.07.2025 |
---|---|---|
Previous Price * | 98.65 USD | 18.07.2025 |
52 Week High * | 113.07 USD | 29.07.2024 |
52 Week Low * | 80.58 USD | 08.04.2025 |
NAV * | 98.26 USD | 21.07.2025 |
Issue Price * | 98.26 USD | 21.07.2025 |
Redemption Price * | 98.26 USD | 21.07.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 374,078,530 | |
Unit/Share Assets *** | 15,644,527 | |
Trading Information SIX |
YTD Performance | +3.96% |
31.12.2024 - 21.07.2025
31.12.2024 21.07.2025 |
---|---|---|
YTD Performance (in CHF) | -8.61% |
31.12.2024 - 21.07.2025
31.12.2024 21.07.2025 |
1 month | +2.46% |
24.06.2025 - 21.07.2025
24.06.2025 21.07.2025 |
3 months | +12.49% |
22.04.2025 - 21.07.2025
22.04.2025 21.07.2025 |
6 months | -1.66% |
21.01.2025 - 21.07.2025
21.01.2025 21.07.2025 |
1 year | -11.36% |
22.07.2024 - 21.07.2025
22.07.2024 21.07.2025 |
2 years | -1.80% |
21.07.2023 - 21.07.2025
21.07.2023 21.07.2025 |
3 years | +5.88% |
21.07.2022 - 21.07.2025
21.07.2022 21.07.2025 |
5 years | -1.74% |
15.09.2020 - 21.07.2025
15.09.2020 21.07.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Vertex Pharmaceuticals Inc | 9.59% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 7.07% | |
Neurocrine Biosciences Inc | 5.04% | |
Guardant Health Inc | 4.67% | |
Gilead Sciences Inc | 4.61% | |
AbbVie Inc | 4.37% | |
Sandoz Group AG Registered Shares | 3.91% | |
Amgen Inc | 3.90% | |
Royalty Pharma PLC Class A | 3.49% | |
Roivant Sciences Ltd Ordinary Shares | 3.33% | |
Last data update | 30.06.2025 |
TER | 0.89% |
---|---|
TER date | 30.11.2024 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.66% |
Ongoing Charges *** | 0.89% |
SRRI ***
|
|
SRRI date *** | 30.06.2025 |